Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Can-Fite Biopharma Ltd American Depositary Shares
(NY:
CANF
)
5.131
+2.161 (+72.77%)
Streaming Delayed Price
Updated: 9:52 AM EDT, Jul 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Can-Fite Biopharma Ltd American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
December 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
December 04, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Recap: Can Fite Biofarma Q3 Earnings
↗
November 30, 2023
Via
Benzinga
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
November 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Recap: Can Fite Biofarma Q1 Earnings
↗
June 01, 2023
Via
Benzinga
Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?
↗
November 21, 2023
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of
Via
Benzinga
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
November 21, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
November 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
October 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
October 26, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
October 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
October 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
September 27, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
September 07, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
August 31, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
August 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
August 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
July 17, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
July 07, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
June 29, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
June 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
June 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
June 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 15, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
May 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 05, 2023
Via
Benzinga
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 02, 2023
Via
Benzinga
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
May 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
